{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.9","value":"4.5"},{"groupId":"OG001","spread":"5.4","value":"4.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"General doctor or PCC for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.9","value":"4.5"},{"groupId":"OG001","spread":"7.6","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"title":"General doctor or PCC for health issue related to MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.3","value":"6.3"},{"groupId":"OG001","spread":"9.7","value":"6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Physical or occupational therapist for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.4","value":"6.2"},{"groupId":"OG001","spread":"6.4","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Physical or occupational therapist for health issue related to MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.0","value":"3.2"},{"groupId":"OG001","spread":"7.4","value":"5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Mental health professional for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.4","value":"3.3"},{"groupId":"OG001","spread":"7.8","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Mental health professional for health issue related to MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.1","value":"4.2"},{"groupId":"OG001","spread":"3.3","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Medical doctor or clinician (specialist) for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.0","value":"4.5"},{"groupId":"OG001","spread":"2.4","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Medical doctor or clinician (specialist) for health issue related to MM"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant consulted (had seen or talked to) following healthcare professionals: general doctor or primary care clinician (PCC) who treats a variety of illnesses for any health issue including MM or related to MM, physical or occupational therapist for any health issue including MM or related to MM, mental health professional (e.g. psychiatrist, psychologist, psychiatric nurse) for any health issue including MM or related to MM, medical doctor or clinician who specializes in particular medical disease or issue (specialist) for any health issue including MM or related to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with responses at Baseline are presented.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1)","title":"HRUPQ: Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Consulted a Healthcare Professional (HCP)","type":"SECONDARY","unitOfMeasure":"number of times consulted a HCP"}